UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

~~of the~~ Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~May 27~~July 30, 2020

AIMMUNE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)



Delaware	001-37519	45-2748244
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

8000 Marina Blvd, Suite 300Brisbane, CA 94005(Address of principal executive offices, including Zip Code)

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (650) 614-5220

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

☐Securities ~~Soliciting~~registered ~~material~~ pursuant to ~~Rule~~Section ~~14a-~~12(b) ~~under~~of the ~~Exchange~~ Act ~~(17 CFR 240.14a-12)~~:

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		AIMT		Nasdaq Global Select Market

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		AIMT		NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 52.0702 ~~Submission~~Results of ~~Matters~~Operations toand aFinancial ~~Vote of Security Holders~~Conditions.

On ~~May 27~~July 30, 2020, Aimmune Therapeutics, Inc. (~~the~~ “~~Company~~Aimmune”) ~~held~~or ~~its Annual Meeting of Stockholders (~~the “~~Annual Meeting~~Company”). Atissued ~~the~~a ~~Annual~~press ~~Meeting,~~release ~~the~~announcing ~~Company’s~~its ~~stockholders~~financial ~~voted~~results onfor ~~three proposals, each of which is described in more detail in~~ the ~~Company’s~~quarter ~~definitive proxy statement on Schedule 14A filed with the Securities~~ and ~~Exchange~~six ~~Commission~~months onended ~~April 9~~June 30, 2020., ~~Only~~and ~~stockholders~~its offinancial ~~record~~position as of ~~the~~June ~~close of business on March 31~~30, 2020,. ~~the~~The ~~record~~Company ~~date~~will ~~for~~conduct ~~the~~a ~~Annual~~conference ~~Meeting,~~call ~~were entitled~~ to ~~vote~~review atits ~~the~~financial ~~Annual~~results ~~Meeting. As~~on ofJuly ~~the record date~~30, 652020,~~222,917~~ ~~shares of the Company’s common stock were outstanding and entitled to vote~~ at ~~the~~4:30 ~~Annual~~p.m., ~~Meeting~~Eastern Time. The ~~tabulation~~full text of the ~~stockholder~~press ~~votes~~release ~~on each proposal brought before the Annual Meeting~~ is furnished as ~~follows:~~Exhibit 99.1 hereto.

~~Proposal~~The 1information in this Item 2.02 ~~The~~of ~~election~~this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of ~~three~~Section ~~directors~~18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to ~~hold~~the ~~office~~liabilities ~~until~~of that Section, or incorporated by reference into any filings of the ~~2023~~Company ~~annual~~made ~~meeting~~under the Securities Act of ~~stockholders~~1933, oras ~~until~~amended, ~~their~~regardless ~~respective~~of ~~successor~~any isgeneral ~~elected:~~incorporation language in the filing unless specifically stated so therein.

Nominee	Votes For		Votes Withheld	Broker Non-Votes
Mark McDade	34,480,200	10,675,109		10,070,278
Dr. Brett Haumann	36,938,323	8,216,986		10,070,278
Stacey Seltzer	36,922,814	8,232,495		10,070,278

Item 9.01 Financial Statements and Exhibits.

Proposal 2. The ratification of the selection, by the audit committee of the board of directors of the Company, of KPMG, LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2020:


Exhibit No.		Description
99.1		Press release dated July 30, 2020
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Votes For		Votes Against		Abstentions
55,074,795		99,299		51,493

As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.

Proposal 3. The approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers:

Votes For		Votes Against		Abstentions		BrokerNon-Votes
44,271,521		798,783		85,005		10,070,278

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AIMMUNE THERAPEUTICS, INC.

~~AIMMUNE THERAPEUTICS, INC.~~

Date: May 28, 2020

/s/ Douglas T. Sheehy

Date: July 30, 2020

/s/ Eric H. Bjerkholt

Douglas T. Sheehy General Counsel and Secretary

Eric H. Bjerkholt

Chief Financial Officer

Filing Compare · Aimmune Therapeutics, Inc.